BRIEF-Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone

Reuters
18 Feb
BRIEF-Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone

Feb 18 (Reuters) - Chimerix Inc CMRX.O:

  • CHIMERIX ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR DORDAVIPRONE AS TREATMENT FOR RECURRENT H3 K27M-MUTANT DIFFUSE GLIOMA

  • CHIMERIX INC - FDA GRANTS PRIORITY REVIEW TO CHIMERIX'S DORDAVIPRONE, PDUFA DATE AUGUST 18, 2025

  • CHIMERIX INC - NO ADVISORY COMMITTEE MEETING PLANNED FOR CHIMERIX'S DORDAVIPRONE NDA

Source text: ID:nGNX2LbQJt

Further company coverage: CMRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10